ClinicalTrials.gg
Status unknownNCT04475224Updated Aug 26, 2022

Phase 3 Study of KP-100IT in Subjects With Acute Spinal Cord Injury

A Phase 3 interventional study of KP-100IT in Acute Spinal Cord Injury, sponsored by Kringle Pharma, Inc.. Status unknown at 5 sites in Japan. Open to participants aged 18 Years to 89 Years. Per ClinicalTrials.gov, last updated 2022-08-26.

Sponsored by Kringle Pharma, Inc. · Phase 3, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Aug 2022), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
25
Allocation
Not applicable
Ages
18 Years to 89 Years
Sex
All
01

Study summary

This study is non-randomized, multicenter, confirmatory study by intrathecal administration of KP-100IT, code of HGF (Hepatocyte Growth Factor ) formulation for intrathecal injection, in subjects with acute spinal cord injury.

02

Conditions studied

  • Acute Spinal Cord Injury

Keywords

  • Hepatocyte Growth Factor
  • HGF
  • KP-100IT
  • KP-100
  • Intrathecal injection
03

In context

Lead sponsor

Kringle Pharma, Inc. is the lead sponsor of 4 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 89 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • At the time of consent (whether oral or written consent), the patient's age is over 18 years old and under 89 years old
  • Patients who have suffered a cervical spinal cord injury within the past 78 hours whose AIS classification was A at 66 - 78 hours after injury-Written has been obtained

Exclusion criteria

Exclusion Criteria:

  • The injury site is C1-C2 or C2-C3
  • The patient cannot start rehabilitation necessary for recovery of function at an early stage, for example because tracheal intubation, tracheotomy, or mechanical ventilatory support is necessary
  • It is predicted that it will not be possible to administer the first dose of the study drug within 78 hours after the cervical spinal cord injury
  • A history of SCI (Spinal cord injury), or abnormal findings in the spinal cavity or marked breakdown of the meninges other than SCI
  • Efficacy and safety cannot be evaluated properly due to such as concurrent multiple external trauma or concurrent organ injury
  • High dose therapy administered for spinal cord injury
  • Disease such as serious liver disorder, renal disease, heart disease, blood dyscrasia, metabolic disease, or infections requiring systemic therapy
  • History of malignant tumor
  • Participation in a clinical study or research of pharmaceuticals or medical devices within 1 month before registration
  • Drug allergies to drugs that will be (or may be) used
  • Administration of the study drug to the site of spinal cord injury is inappropriate for a reason such as intrathecal infection or intrathecal mass
  • Problems with the subject's ability to give in person
  • The subject is breastfeeding or possibly pregnant
  • The subject cannot be expected to survive more than 180 days after the start of administration of the study drug, in the judgement of the investigator
  • It is inappropriate for the subject to be included in the study, in the judgement of the investigator
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
25 participants (estimated)

Study arms

  • Other
    Open-label

    Drug: KP-100IT

Interventions

  • Intrathecal injection of 0.6 mg HGF starting at 72 hours since the injury and repeating weekly 5 times

    Also known as: Hepatocyte Growth Factor, HGF

06

What researchers measure

Primary outcomes

  1. Percentage of subjects with an improvement of at least two AIS (American Spinal Injury Association) grade, A to C/D, at 24 weeks after administration

    Time frame: 24 weeks

Secondary outcomes

  1. Time course of ASIA motor score (total/ upper extremity / lower upper extremity)

    Time frame: up to 24weeks

  2. Time course of ASIA sensory score

    Time frame: up to 24weeks

  3. Time course of AIS classification

    Time frame: up to 24weeks

  4. Time course of modified Frankel classification

    Time frame: up to 24weeks

  5. Time course of neurological level of injury

    Time frame: up to 24weeks

  6. Percentage of subjects improving by at least 10 points on the ASIA motor score at 12 weeks and 24 weeks after administration relative to before study drug administration

    Time frame: 12 weeks and 24 weeks

  7. Time courses of plasma concentration and cerebrospinal fluid concentration of KP-100IT after intrathecal administration

    Time frame: up to 24weeks

  8. Evaluation of adverse events

    Time frame: up to 24weeks

07

Study locations

5 of 5 sites recruiting
  • Spinal Injuries Center
    Iizuka, Fukuoka 820-8508, Japan
    Recruiting
    • Takeshi Maeda, MD, PhD · Contact+81-948-24-7500
    • Takeshi Maeda, MD, PhD · Principal investigator
  • Hokkaido Spinal Cord Injury Center
    Bibai, Hokkaido 072-0015, Japan
    Recruiting
    • Kota Suda, MD, PhD · Contact+81-126-63-2151
    • Kota Suda, MD, PhD · Principal investigator
  • Japanese Red Cross Kobe Hospital
    Kobe, Hyogo 651-0073, Japan
    Recruiting
    • Yasuo Ito, MD, PhD · Contact+81-78-231-6006
    • Yasuo Ito, MD, PhD · Principal investigator
  • Aijinkai Rehabilitation Hospital
    Takatsuki, Osaka 569-1116, Japan
    Recruiting
    • Mihoko Matsuoka, MD,PhD · Contact+81-72-683-1212
    • Mihoko Matsuoka, MD, PhD · Principal investigator
  • Murayama Medical Center
    Musashimurayama, Tokyo 208-0011, Japan
    Recruiting
    • Tsunehiko Konomi, MD, PhD · Contact+81-42-561-1221
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2020 (actual). Primary completion is estimated for Dec 2022, 29 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 12, 2020
First posted
Jul 17, 2020
StartActual
Jul 13, 2020
Primary completionEst.
Dec 31, 2022
CompletionEst.
Jun 30, 2023
Last update
Aug 26, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 26, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04475224
Lead sponsor
Kringle Pharma, Inc.
Responsible party
Sponsor
First posted
Jul 17, 2020
Start date
Jul 13, 2020
Primary completion
Dec 31, 2022 (estimated)
Completion
Jun 30, 2023 (estimated)
Last update
Aug 26, 2022

Study contacts

Etsuro Hashimura
Contact
hashimura@kringle-pharma.com
+81-72-641-8739
Daichika Hayata
Contact
hayata@kringle-pharma.com
+81-72-641-8739
Etsuro Hashimura
study director · Kringle Pharma, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: KP-100IT

Start the discussion